Exelon and Constellation Energy Announce Merger April 28, 2011 Creating a Clean, Competitive Future.
QIAGEN and DIGENE Announce Merger A New … and DIGENE Announce Merger A New Market and Technology...
Transcript of QIAGEN and DIGENE Announce Merger A New … and DIGENE Announce Merger A New Market and Technology...
04.06.2007 14:05 Sample & Assay TechnologiesQIAGEN / DIGENE Investor Call - June 4, 2007 - 1 -
QIAGEN and DIGENE Announce Merger
A New Market and Technology Leader inMolecular Diagnostics
June 4, 2007, 8:30am EST, 13:30 GMT, 14:30 CET
Conference Call Outline:
1. 30 min PresentationPeer M. Schatz, CEO, QIAGENRoland Sackers, CFO, QIAGENDaryl J. Faulkner, CEO, DIGENEJoe P. Slattery, CFO, DIGENEDr. Solveigh Mähler, Director IR, QIAGENAlbert Fleury, IR, DIGENE
2. 30 min Q&A sessionDue to time restrictions we wouldlike to ask for a maximum of TWO questions per caller.
ENERGY\Commuications\final Sample & Assay Technologies- 2 -QIAGEN / DIGENE Investor Call, June 4, 2007
Joint Safe Harbor
.Remarks that we make during this call about future expectations, plans and prospects may include forward-looking statements. There are risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements, as a result of various important factors, including those that are discussed in QIAGEN's and DIGENE'smost recent filings with the SEC, and the risks related to the transaction itself. Please refer to those filings, which are publicly available on the SEC's website, for a full description of those factors. In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures "adjusted EPS," “adjusted operating income,” “adjusted net income,” “adjusted operating margin” and “EBITDA”. None of these financial measures is a measure of operating performance under GAAP. We believe that the use of these non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts our performance, especially when comparing such results to previous periods or forecasts. When analyzing our operating performance, investors should not consider these non-GAAP measures as a substitute for diluted EPS, income from operations, net income, or operating margin prepared in accordance with GAAP..In the attached presentation, QIAGEN will use the term molecular diagnostics. The use of this term in reference to certain countries, such as the United States, is limited to products subject to regulatory framework. Current QIAGEN molecular diagnostics products are 34 EU CE IVD assays, six EU CE IVD sample preparation products, one 510k PAX RNA product, nine China SFDA IVD assays and 98 general purpose reagents
ENERGY\Commuications\final Sample & Assay Technologies- 3 -QIAGEN / DIGENE Investor Call, June 4, 2007
Transaction Overview
Purchase Price: US$ 61.25 per share, a 37% premium to prior close
Purchase Consideration: DIGENE shareholders may elect to receive for each DIGENE share either US$ 61.25 pershare in cash or 3.545 QIAGEN shares, subject to pro ration (55%/45% cash/stock)
Pro forma Ownership: QIAGEN: 78%; DIGENE: 22%
.Transaction Structure: Exchange offer, followed by a merger - cash stock election in both transactions
.Management: Peer Schatz, QIAGEN CEORoland Sackers, QIAGEN CFO
.Customary Approvals: Tender of majority of DIGENE shares, QIAGEN shareholder approval and customary regulatory approvals
.Financing: Stock, surplus cash, committed financing
.Timing of Closing: Expected August/September 2007
Creating Value for DIGENE and QIAGEN Shareholders
ENERGY\Commuications\final Sample & Assay Technologies- 4 -QIAGEN / DIGENE Investor Call, June 4, 2007
0
50
100
150
200
250
2003 2004 2005 2006 2007E0
5
10
15
20
25
30
35
40
45RevenuesOperating income
QIAGEN and DIGENE at a GlanceU
S$ m
illio
ns
Revenues excluding the synthetic DNA business unit, sold in Q2 2004
World’s leading provider ofSample & Assay Technologies
Founded: 1984Headquarters: Hilden, Germany
Germantown, MDVenlo, NL
Employees: 1,990Rev 2006 (US$ m) 466Listings: NASDAQ: QGEN
Frankfurt: QIA
Market leader in HPV MDx testing, only FDA approved test
Founded: 1987Headquarters: Gaithersburg, MDEmployees: 570Rev 2006 (US$ m) 178Listing: NASDAQ: DIGE
DIGENE figures converted to calendar year (CY)
050
100150200250
300350400450
500550
2003 2004 2005 2006 2007E0
20
40
60
80
100
120
140
160RevenuesOperating income
US$
mill
ions
US$
mill
ions
US$
mill
ions
Revenues CAGR 2003-2006 15%
Revenues CAGR 2003-2006 32%
ENERGY\Commuications\final Sample & Assay Technologies- 5 -QIAGEN / DIGENE Investor Call, June 4, 2007
Leader in key segment of MDx: HPV testing
The DIGENE® HPV Test portfolio is the only FDA-approved test portfolio for the human papillomavirus (HPV)
Exclusive IP positions on key high-risk types
Regulatory leadership
Focus on women’s health
Portfolio includes molecular diagnostic products forHPV (a run-rate of over 10 million tests)Chlamydia and gonorrheaBlood viruses such as hepatitis B and CMV
Proprietary Hybrid Capture® technology for molecular testing invirtually any laboratory setting
Headquartered in Gaithersburg, Maryland
Overview of DIGENE Corporation
Leader in Molecular Diagnostics in Critical Area of Women’s Health
ENERGY\Commuications\final Sample & Assay Technologies- 6 -QIAGEN / DIGENE Investor Call, June 4, 2007
QIAGEN and DIGENEA Decade-Long Partnership in Molecular Diagnostics
10+ year partnership between QIAGEN and DIGENE
DIGENE products integrate QIAGEN sample and assay technologies
Example: Rapid Capture® systemCore platform of DIGENEFDA-listed instrumentCo-developed and manufactured by QIAGENDIGENE sole marketerOver 100 instruments now placed
Next generation platform development programs
Partnership – Similar cultures – Focus - Excellence
ENERGY\Commuications\final Sample & Assay Technologies- 7 -QIAGEN / DIGENE Investor Call, June 4, 2007
The Combination AcceleratesDIGENE’s Commercialization and Development Goals
Highly attractive consideration for DIGENE shareholdersSignificant premium and value delivered todaySignificant combined upside potential
QIAGEN’s unparalleled sample and assay technology breadthcreates opportunities for future
Adds key assay technologies such as multiplexing (QIAplex), PCR, isothermal technologiesAdds key sample technologies such as DNA processing from cervical swabsQIAGEN’s broad assay portfolio offers new value for DIGENE’s customers andNext generation platform programs
QIAGEN’s global sales strength accelerates DIGENE’s rapid international rollout
DIGENE can utilize QIAGEN’s operations and infrastructure for next phase of growth
QIAGEN’s Breadth and Platforms + DIGENE’s Content
ENERGY\Commuications\final Sample & Assay Technologies- 8 -QIAGEN / DIGENE Investor Call, June 4, 2007
The Combination AcceleratesQIAGEN’s Molecular Strategy
DIGENE’s highly focused strategy in MDx is a exceptional fit with QIAGENQIAGEN’s strategy: leadership in “Sample & Assay Technologies”– in research, pharma, applied testing and MDxSame target customers in MDxSuperb brands and reputations
HPV testing is the fastest growing segment in MDxOver $1 billion market potentialDIGENE’s strong IP positions in HPV – over 100 subtypes; approximately 13 are high-riskHPV bridges QIAGEN’s virology leadership into emerging,fast growing oncology molecular diagnostics segment
Unique regulatory position – only FDA-approved test for HPVGreat fit with QIAGEN’s emerging assay pipeline and platforms
Enhanced growth profile and combined profitability leads tostrong value creation
QIAGEN’s Breadth and Platforms + DIGENE’s Content
ENERGY\Commuications\final Sample & Assay Technologies- 9 -QIAGEN / DIGENE Investor Call, June 4, 2007
The Combination Creates Real Value
Market and technology leadership in molecular diagnostics*Over $350 million of molecular diagnostics revenueTargeting > $800 million in total revenues in 2008
Unique technology and product portfolioLeading in breadth and depth in molecular testingLeader in HPV segment; >$1 billion market potential
Industry leading sales channel to realize technology potentialOver 300 professionals in MDx salesOver 1,000 sales professionals overall
Excellent foundation for future expansion and growthTruly global sales and marketing presenceLeading technologies and R&DExpanded options for future growth opportunities
World-class capabilities and organization to ensure success
Compelling financial profile and value creation opportunityEnhanced growth profile Increased combined profitability
QIAGEN’s Breadth and Platforms + DIGENE’s Content * Ex blood banks and viral load
VAL UE
ENERGY\Commuications\final Sample & Assay Technologies- 10 -QIAGEN / DIGENE Investor Call, June 4, 2007
QIAGEN Digene
Run-rate Sales as of Q1 '07 512 210
Sales in MDx (approximately)
154 210
Sales strength Global North America
Sales force in MDx (approximately)
150 170
Sales force target in MDx Clinical LaboratoriesClinical Laboratories,
Physicians
Assay portolioBroad: 120 tests - virology,
microbiology, genetic, pharmacogenetic
HPV
Technology portfolio Strong - sample and assay technologies
HC2
Operations US, Germany, Switzerland, China
US
International Subsidiaries 29 7Employees 1990 570
Highly Synergistic Capabilities and Assets
Highly Synergistic Capabilities and Assets
ENERGY\Commuications\final Sample & Assay Technologies- 11 -QIAGEN / DIGENE Investor Call, June 4, 2007
Combined Revenue Distribution – Highly ComplementaryBased on Q1 2007
By Product Groups
By Geographic Regions
By Customer Groups
Europe46%
NorthAmerica
39%
Asia13%
NorthAmerica
85%
EU12%
NorthAmerica
52%
EU36%
Asia9%
Consumables89%
Consumables92%
Consumables90%
Instruments10%
Instruments8%
Instruments10%
MDx100%
MDx48%
MDx27%
Pharma24% Pharma
17%
AT11%
AT8%
Biomedical18%
Research20%
All figures are estimates +
RoW
Research27%
ENERGY\Commuications\final Sample & Assay Technologies- 12 -QIAGEN / DIGENE Investor Call, June 4, 2007
A Critical Disease Target: Humanpapilloma Virus (HPV)
Cervical cancer is the #2 cancer for women worldwideWW over 470K cases/year causing more than 230K deathsIn the US almost 10K cases/year, almost 4K deathsOne woman dies every two minutes from cervical cancer
HPV is the proven cause of cervical cancer
The DIGENE HPV Test is the emerging “standard of care” for cervical cancer screening
Extensive and expanding clinical dataMedical community support – recognized in major clinical guidelinesWell established reimbursementStrong partnerships with major reference labs
Pool of “eligible” candidates for the DIGENE HPV Test is large and broadly untapped
Prevalence of HPV in Cervical Cancers Worldwide 99.7%
ENERGY\Commuications\final Sample & Assay Technologies- 13 -QIAGEN / DIGENE Investor Call, June 4, 2007
DIGENE HPV Test is Playing a Key Role in Women’s Health
HPV Screening Can Best Fight Cervical Cancer
84.4%
100%
57.7%
0%
10%
20%
30%
40%
50%
Conventionalcytology
Liquid cytology The Digene HPVtest
Sensitivity: High Grade Cervical Disease
Cervical cancer is more prevalent in women age >301/3 of cervical cancers in woman with a normal PapClinical practice guidelines now recommend combined screening (HPV+Pap for women >30 yrs)
The DIGENE HPV TestClinical results published on > 200,000 womenFirst FDA-approval received in 1999
ACOG Guidelines cites studies showingHPV testing sensitivity up to 100% for CIN 2/3 and cancer (cervical intra-epithelial neoplasia)Cites studies showing liquid-based cytology may miss 15-35% of CIN 2/3 and cancerCombined HPV testing with cervical cytology has a negative predictive value for CIN 2/3 of 99-100%
ENERGY\Commuications\final Sample & Assay Technologies- 14 -QIAGEN / DIGENE Investor Call, June 4, 2007
Significant Untapped Potential for HPV Testing
Increasing adoption into medical guidelines
Vaccine campaigns to promote awareness of HPV and cervical cancer
New genotyping tests will expand market to include HPV positive patients
Increased spending on global DTC (direct-to-consumer) is increasing awareness
Significant untapped potential in developing world
Substantial Growth Potential - Increasing Awareness
U.S.Current tests: ~ 8.4MPenetration rate: ~ 22%
EuropeCurrent tests: ~ 2.0MPenetration rate: ~ 6%
Asia/Latin America:Current tests: 0.9MPenetration rate: ~ 3%
Asia/Latin America~ $280 million
U.S.~ $490 million
Europe~ $350 million
Total: >$1.0 billion
ENERGY\Commuications\final Sample & Assay Technologies- 15 -QIAGEN / DIGENE Investor Call, June 4, 2007
Vaccines are a Compelling Growth Driver for HPV Testing
Vaccines Are a Compelling Growth Driver for HPV Testing
Significant marketing budgets advocating importance
Target age groupsTarget vaccination age: 11-12 yearsApproved vaccination age: 9 to 26 yearsTarget testing age: >30 yearsIt would take >20 years to phase in
Vaccinations Limited to 2 “high risk” HPV types(70% of cancers)DIGENE HPV Test tests for 13 types
ExperienceVaccine efficacy drops significantly for those already exposed to HPVDuration of effectiveness of vaccine uncertainPossibility of genotype replacement is unknown
ENERGY\Commuications\final Sample & Assay Technologies- 16 -QIAGEN / DIGENE Investor Call, June 4, 2007
Tangible Opportunities for Future Growth Synergies
Significant Growth Synergies
Exciting near-term product synergies:
■ Multiplexing technologies for future genotyping application
■ Sample preparation■ Next-generation assay technologies■ Assay breadth in woman’s health
Exciting other synergies include:
■ QIAGEN is key supplier to vaccine developers■ Manufacturing capacity■ Channel lends itself to many future assay
opportunities■ FastHPV platform in developing countries,
QIAGEN has channel■ Next generation instrumentation■ And many more to come…
ENERGY\Commuications\final Sample & Assay Technologies- 17 -QIAGEN / DIGENE Investor Call, June 4, 2007
QIAGEN and DIGENE - Direct NeighborsGermantown and Gaithersburg MD
Companies are 5 minutes apart (2.8 miles)
ENERGY\Commuications\final Sample & Assay Technologies- 18 -QIAGEN / DIGENE Investor Call, June 4, 2007
World-Class Capabilities and Organizationto Ensure Success
Great management breadth and depth Strong leaders from both companiesLeading expertise in molecular diagnosticsand life sciencesStrong foundation for collaboration builtupon 10+ year partnership
Similar cultures and strong working relationship
Strong synergies – growth allows retention of talent base
Integration plan well-developed12 month process, clear timelinesMirrored teamsBeing neighbors a big advantageMaryland: U.S. Headquarters
QIAGEN has proven track record in successful integrations – 12 companies in last 3 years
We are
Significant Growth Potential - Increasing Awareness
ENERGY\Commuications\final Sample & Assay Technologies- 19 -QIAGEN / DIGENE Investor Call, June 4, 2007
A New Leader in Molecular Diagnostics
Consistent with strategies of both companiesQIAGEN: leadership in sample and assay technologies –in research, pharma, applied testing and MDxDIGENE: a leader in HPV; poised for next wave of growth
Creating a new leader in MDx with broad synergiesTechnologyContentChannel / InfrastructureManagement
Transaction providesSignificant premium to DIGENE shareholdersParticipation in value creation post mergerAttractive earnings profile for QIAGENCombined entity with financial strength and flexibility
Excellent basis for future growthMost exciting areas in MDx – links into oncologyInfrastructure can enhance future opportunities
Creating Value with our Strategy
ENERGY\Commuications\final Sample & Assay Technologies- 20 -QIAGEN / DIGENE Investor Call, June 4, 2007
Financial Rationale
Enhancing revenue and EPS growth
Revenue synergy opportunities
Cost synergy opportunities
Accretive to adjusted EPS in the first year after closing
Significantly accretive to 2009 EPS and EPS growth thereafter
Strong cash flow generation
Revenue Enhancing - Accretive – Cash Flow Generating
ENERGY\Commuications\final Sample & Assay Technologies- 21 -QIAGEN / DIGENE Investor Call, June 4, 2007
0
100
200
300
400
500
600
700
800
2003 2004 2005 2006 2007E
QIAGEN + DIGENE Revenue Growth 2003 – 2007E
US$ millions
CAGR Q 2003-2006 = 15%CAGR D 2003-2006 = 32%CAGR Total 2003-2006 = 19%
QIAGEN revenues excluding the synthetic DNA business unit, sold in Q2 2004 DIGENE revenues converted to calendar year (CY)
QIAGEN – Continuous Double Digit Revenue Growth Rates
DIGENEQIAGEN
ENERGY\Commuications\final Sample & Assay Technologies- 22 -QIAGEN / DIGENE Investor Call, June 4, 2007
0
40
80
120
160
200
2003 2004 2005 2006 2007E
QIAGEN + DIGENE Operating Income 2003 – 2007E1
QIAGEN – Operating Income Strongly Benefits from Synergies
US$ millions
CAGR Q 2003-2006 = 17%CAGR D 2003-2006 = 235%CAGR Total 2003-2006 = 25%
DIGENEQIAGEN
1. Operating income excludes acquisition, integration and relocation related charges, as well asamortization of acquired IP and equity-based compensation (SFAS 123R)DIGENE net income converted to CY
ENERGY\Commuications\final Sample & Assay Technologies- 23 -QIAGEN / DIGENE Investor Call, June 4, 2007
0
20
40
60
80
100
120
140
160
2003 2004 2005 2006 2007E
QIAGEN + DIGENE Net Income 2003 – 2007E1
QIAGEN – Accelerating Earnings Development
1. Net income excludes acquisition, integration and relocation related charges as well asamortization of acquired IP and equity-based compensation (SFAS 123R)DIGENE net income converted to CY
US$ millions
CAGR Q 2003-2006 = 22%CAGR D 2003-2006 = 157%CAGR Total 2003-2006 = 31%
DIGENEQIAGEN
ENERGY\Commuications\final Sample & Assay Technologies- 24 -QIAGEN / DIGENE Investor Call, June 4, 2007
Synergy Opportunities – Near and Long Term
Cost synergies – Near and long termSavings of US$35 million to US$45 million in 2008Sustainable reduction of cost of goods soldEliminated redundant expenses, public company costsAugmented R&D capabilities to drive product developmentExpanded applicability of QIAGEN’s instrument platformsFurther synergies to be determined through integration plan
Revenue synergies – Near and long termGeographic sales synergies, effect of increased direct presenceProduct synergies to enhance higher organic growthQIAGEN sales force and customer relationships are key
QIAGEN track record of successful acquisitions and integrations
Integration project team in place. Led by:Douglas Liu, QIAGEN VP Global OperationsThomas Schweins, QIAGEN VP Corporate Strategy & MarketingJoe Slattery, DIGENE CFODoug White, DIGENE SVP Commercial Operations
ENERGY\Commuications\final Sample & Assay Technologies- 25 -QIAGEN / DIGENE Investor Call, June 4, 2007
Contribution to Fiscal Year 2007
(0.03) – (0.04)
58 - 60
Adj. EPS, US$1
Net sales, US$ m2
Q4 2007
1. Adjusted EPS excludes acquisition, integration and relocation related charges as well as amortization ofacquired IP and equity-based compensation (SFAS 123R)
2. Based upon existing consensus estimates for DIGENE
Q3 2007
Assumes current consensus estimates for DIGENERevenue and EPS allocation dependent on final closing dateExpected adj. EPS1 for the third quarter approx. US$ (0.01) – (0.02)
ENERGY\Commuications\final Sample & Assay Technologies- 26 -QIAGEN / DIGENE Investor Call, June 4, 2007
Contribution and Accretion to Fiscal Year 2008
260 - 270Net sales, US$ m
+Synergy revenues
-Instrument and other product sales to DIGENE
28% - 30%Adj. Operating margin1
FY 2008All figures reflect calendar year estimates
0.02 – 0.04Adj. EPS, US$1
260 - 270Net sales, US$ m
1. Adjusted operating margin and EPS excludes acquisition, integration and relocation related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R)
Significantly Accretive to 2009 EPS and Future EPS Growth
ENERGY\Commuications\final Sample & Assay Technologies- 27 -QIAGEN / DIGENE Investor Call, June 4, 2007
Combined Financial Strength
Strong balance sheetEquity ratio: > 45 %
Strong cash flow generationCash flow in 2008: > US$100 millionEBITDA 2008: > US$250 million
Mid term outlook / strong margin improvement
Organic Revenue growth: > 15% Adj. EPS1 growth: > 20%Gross Margin: > 70%Operating Margin: > 30%
1. Adjusted EPS excludes acquisition, integration and relocation related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R)
ENERGY\Commuications\final Sample & Assay Technologies- 28 -QIAGEN / DIGENE Investor Call, June 4, 2007
Roadmap to Completion
Commence exchange offer for both cash and stock in June
Queen shareholder vote in early July
HSR approval
Complete Tender Offer
Transaction close expected August/September 2007
ENERGY\Commuications\final Sample & Assay Technologies- 29 -QIAGEN / DIGENE Investor Call, June 4, 2007
Creation of a market and technology leader in MDx*QIAGEN’s breadth in sample and assay technologies meets DIGENE’s leadership in a key segment of MDxUnique technology, content and product portfolioComprehensive sales and marketing channel to realize technology potentialExcellent foundation for expansion and growthWorld-class capabilities and organization to ensure successSubstantial growth opportunities through
- Expansion: geographical and new customer groups- New products/applications (oncology testing)
Significant product and cost synergiesSmooth integration expected due to long partnershipAccretive to adj. EPS in 2008 and significantly accretive to EPS and EPS growth thereafter
Transaction Highlights
Combination Creates Value * Ex blood banks and viral load